Enabling Major Advances For Breast Cancer Care: The View From AstraZeneca’s Head of U.S. Breast Cancer Alison Dziarmaga

Over the past year alone, AstraZeneca, the global pharmaceuticals giant, has emerged as one of the industry’s most influential forces in breast cancer treatment, expanding a franchise that now includes four FDA-approved therapies spanning multiple stages and subtypes of the disease. Most remarkably, the company secured three FDA approvals in a single week–two separate new FDA indications for Enhertu and a new Datroway approval: an unprecedented milestone that underscores both the speed of innovation and the breadth of its scientific ambition.

The approvals represent meaningful progress across the breast cancer landscape.

Jointly developed and commercialized by AstraZeneca and the Japanese pharmaceutical company Daiichi Sankyo, Enhertu (trastuzumab deruxtecan) is an antibody-drug conjugate (ADC)–part of a new class of targeted medicines that aim to deliver chemotherapy agents directly to cancer cells–and continues to redefine the treatment paradigm in HER2-positive disease, a type of breast cancer characterized by an excess of the HER2 protein that drives 15% to 20% of all breast cancer diagnoses. Originally introduced for patients with cancer that has spread, the therapy has steadily moved earlier in treatment. New approvals now extend its use into both the neoadjuvant setting before surgery and the adjuvant setting after surgery, offering physicians additional tools at a stage where the ultimate goal is cure.

Meanwhile, Datroway (datopotamab deruxtecan), another ADC developed through the same partnership, recently gained approval for metastatic triple-negative breast cancer patients who are not eligible for immunotherapy—a population with significant unmet need and historically limited options.

Together with its broader portfolio, AstraZeneca now has therapies that address HER2-positive disease across multiple stages, HER2-low and HER2-ultralow tumors, hormone receptor-positive breast cancers, and metastatic triple-negative breast cancer.

But approvals alone do not improve outcomes.

One of the company’s central priorities is ensuring these scientific breakthroughs extend beyond major academic cancer centers and into community oncology practices, where most patients receive care.

“Reaching patients and those physicians in the community is critical and essential and a huge part of our mission,” Dziarmaga said. “We continue to learn, we continue to listen to what they tell us, and we really try to reach people where they are.”

That effort includes educating physicians through forums like ASCO, the largest gathering of clinical oncologists in the world, developing digital resources, and creating patient-facing educational initiatives designed to empower people to participate in treatment decisions.

Because innovation only fulfills its promise when it reaches the people who need it most.

“There is still a lot of work to be done once you get an approval,” Dziarmaga noted. “We continue to drive that work, that awareness, that education.”

As breast cancer treatment becomes increasingly biomarker-driven and personalized, AstraZeneca’s strategy is not simply to develop new medicines. It is to ensure those advances translate into real-world impact, bringing more options, better outcomes, and renewed hope to patients wherever they receive care.

Learn more about SurvivorNet's rigorous medical review process.